Evolent Health, Inc. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2024, for Evolent Health, Inc. (NYSE: EVH). Evolent is a market leader in value-based care solutions, connecting care for patients with complex conditions such as cancer, cardiovascular disease, and musculoskeletal diagnoses. The company operates through a single reportable segment, providing specialty care management, total cost of care management, and administrative services to health plans and providers. In 2024, the company completed the acquisition of Machinify, Inc. to enhance its AI capabilities and continued to integrate its "One Evolent" strategy.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Revenue | $2,554.7 million | $1,963.9 million | +30.1% |
| Cost of Revenue | $2,187.4 million | $1,503.4 million | +45.5% |
| Operating Loss | $(40.5) million | $(71.2) million | Improvement of $30.7 million |
| Net Loss (Common Shareholders) | $(93.5) million | $(142.3) million | Improvement of $48.8 million |
| Operating Cash Flow | $18.8 million | $142.6 million | Decrease of $123.8 million |
| Cash and Restricted Cash | $178.5 million | $223.5 million | Decrease of $45.0 million |
| Total Debt (Principal) | $675.0 million | $675.0 million | No Change |
| Goodwill | $1,137.3 million | $1,116.5 million | +$20.8 million |
Note: Cost of revenue increased significantly due to higher medical claims costs in the Performance Suite, driven by oncology costs and disease prevalence. Operating cash flow decreased primarily due to timing of partner payments and reductions in claims reserves.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 30.1% increase, primarily from new and existing Performance Suite contracts ($512.1 million) and the transition of a customer from the Specialty Technology and Services Suite to the Performance Suite ($97.7 million).
- Margin Compression: Cost of revenue as a percentage of revenue increased from 76.6% in 2023 to 85.6% in 2024. This was caused by higher-than-expected medical costs in the second half of 2024, specifically in oncology, and the receipt of higher expense claims data from partners for prior periods.
- SG&A Reduction: Selling, general, and administrative expenses decreased by 26.5% to $263.1 million, largely due to the completion of the 2023 Repositioning Plan, lower professional fees, and reduced personnel costs.
- Acquisitions: Completed the acquisition of Machinify assets for $28.5 million in August 2024 to leverage AI for clinical reviews.
- Debt Activity: While total principal debt remained stable at year-end, the company amended its Credit Agreement in December 2024 to add $200 million in new term loan facilities and $50 million in revolver capacity. In January 2025, the company drew $200 million on these new facilities.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted that high medical cost inflation in the second half of 2024 was driven by a confluence of factors including increased disease prevalence, Medicaid redetermination-based adverse selection, and rapid increases in unit costs for specialty pharmacy. The company expects these dynamics to continue impacting financial results but anticipates contractual protections and clinical interventions will help offset costs over time.
Outlook: The company believes its current cash and cash equivalents are sufficient to meet working capital requirements for at least the next twelve months. It plans to use proceeds from recent debt draws for general corporate purposes, including working capital and managing future liabilities.
Key Risks and Contingencies:
- Partner Concentration: The top four partners (Humana, Molina, Florida Blue, and Cook County Health) accounted for approximately 57.4% of 2024 revenue. Loss or renegotiation of these contracts poses a significant risk.
- Performance-Based Risk: The company assumes financial risk for the cost of care under its Performance Suite. Inaccurate predictions of exposure or unexpected cost increases (e.g., oncology) can materially impact profitability.
- Regulatory Environment: Changes in federal and state laws regarding Medicare, Medicaid, and prior authorization (including potential impacts from the new Trump administration) could adversely affect business operations.
- Debt Obligations: The company has significant debt obligations, including $575 million in convertible notes and a Tax Receivables Agreement (TRA) liability of $108.1 million. Failure to service debt or meet TRA obligations could impact liquidity.
- Goodwill Impairment: While no impairment was recorded in 2024, the company holds $1.1 billion in goodwill. A sustained decrease in share price or adverse changes in forecasts could trigger future impairment charges.
Investor Verification Checklist
- Medical Cost Trends: Verify the sustainability of the 85.6% cost of revenue ratio and the specific drivers of the oncology cost increases mentioned in the MD&A.
- Partner Contract Renewals: Monitor the status of contracts with the top four partners, particularly Cook County Health and Hospitals System, which represented 11.5% of revenue and 45.8% of accounts receivable.
- Liquidity and Debt Covenants: Review the terms of the new Credit Agreement amendments and the company's ability to meet leverage ratios and liquidity tests, especially given the recent $200 million draw in January 2025.
- Tax Receivables Agreement (TRA): Assess the potential cash outflow impact of the $108.1 million TRA liability and the company's ability to generate taxable income to utilize the underlying tax benefits.
- Claims Reserve Accuracy: Evaluate the actuarial assumptions used for the $318.7 million reserve for claims and performance-based arrangements, as adjustments to these reserves directly impact net income.